DICE Therapeutics, Inc.
DICE · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28,201 | $23,661 | $20,089 | $14,730 |
| G&A Expenses | $11,296 | $7,914 | $6,361 | $6,439 |
| SG&A Expenses | $11,296 | $7,914 | $6,361 | $6,439 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39,497 | $31,575 | $26,450 | $21,169 |
| Operating Income | -$39,497 | -$31,575 | -$26,450 | -$21,169 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,681 | $5,929 | $3,226 | $619 |
| Pre-Tax Income | -$34,816 | -$25,646 | -$23,224 | -$20,550 |
| Tax Expense | $0 | -$5,929 | -$609 | -$619 |
| Net Income | -$34,816 | -$19,717 | -$22,615 | -$19,931 |
| % Margin | – | – | – | – |
| EPS | -0.74 | -0.42 | -0.5 | -0.53 |
| % Growth | -76.2% | 16% | 5.7% | – |
| EPS Diluted | -0.74 | -0.42 | -0.5 | -0.53 |
| Weighted Avg Shares Out | 47,310 | 47,193 | 45,431 | 37,480 |
| Weighted Avg Shares Out Dil | 47,310 | 47,193 | 45,431 | 37,480 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,681 | $5,929 | $3,697 | $702 |
| Interest Expense | $0 | $0 | $471 | $83 |
| Depreciation & Amortization | $687 | $5,929 | $3,697 | $1,297 |
| EBITDA | -$34,129 | -$25,646 | -$19,056 | -$19,872 |
| % Margin | – | – | – | – |